About Us
The core of ZuriMED is built by its people. Our interdisciplinary and diverse team is backed by a strong board of directors comprised of world renowned experts. Together we aim to push the boundaries of current orthopaedic solutions using our innovative technologies.
ZuriMED is located in the heart of Zürich in Switzerland as part of the Swiss health cluster. Surrounded by world-leading universities and orthopaedic healthcare institutes, we have a unique access to high-quality labs, testing facilities, and exceptionally educated talents.
The startup spun off from the University and ETH Zürich and is supported by the Balgrist Beteiligungs AG. Therefore, we can benefit from close collaborations with research groups and clinicians.
Our Team
Our young and ambitious team is built of highly skilled individuals with diverse backgrounds and expertise from pioneering research institutes and companies. Together, we strive to develop breakthrough technologies and build innovative products.
Xiang Li
Elias Bachmann
Pol Banzet
Sascha Brun
Andrea Möhl
Sebastian Arevalo
Ronja Senn
Catherine Trojer Marcelo
Mariano Perez Chaher
Ricardo Ribeiro
Esteban Doig Cramer
Carlota Sole Escobar
Esteban Ongini
Janick Eglauf
Dominic Spothelfer
Cornelius Schlegel
Simon Schnydrig
Blorenta Murseli
Luana Hess
Cherilyn Camichel
Alicia Wirz
Maria Doikova
Board of Directors
Our Board of Directors is comprised of world-leading scientists, consultants and clinicians supporting the company in their field of expertise.
Prof. Dr. Jess Snedeker
President of the Board of Directors
Ulrich Looser
Member of the Board of Directors
Dr. med. Dominique Tschudi
Vice-President of the Board of Directors
Dr. Helen (Ying) Yang
Member of the Board of Directors
Dr. Xiang Li
Member of the Board of Directors
Prof. Dr. Robert Frigg
Member of the Board of Directors
Chan-Yuan Lu
Member of the Board of Directors
History
Scroll through our company’s history and explore the most significant milestones that have shaped ZuriMED’s past.
2023 | ZuriMED closes Series-A financing round & receives Innosuisse Swiss Accelerator Grant
The financing round was led by Chindex Medical Limited (Hong Kong), followed by Yellowstone Holding AG (Geneva) and a group of private investors that includes leading orthopaedic surgeons from Switzerland, Germany, France, and the United States. An additional non-diluting funding from Innosuisse will greatly expedite the development and regulatory registration process of a second clinical indication.
2022 | ZuriMED obtains Innosuisse Scale-up Award & Innosuisse Project Grant
Thanks to this award, ZuriMED can access the second phase of the Scale-up Coaching program to further accelerate the growth in Switzerland and the expansion into new global markets. The Project Grant supports the co-development with research partner University Hospital Balgrist on ZuriMED’s breakthrough technology for soft tissue repair.
2021 | ISO 13485 certificate obtained & First-in-man-study finished
ZuriMED gets ISO 13485 certified by BSI and the clinical trial run by the Balgrist University Hospital with 56 patients from July 2017 to June 2021, showing safety of the investigated device, has been completed.
2020 | ZuriMED closes a license deal with an international medical device company
One of ZuriMED’s endocortical fixation technologies for soft tissue repair has been licensed to an international medical device company. A strategic partnership has been established to work together to bring this technology to clinical applications.
2019 | ZuriMED obtains the Innosuisse Certificate
The company has now obtained the Innosuisse certificate in recognition for the potential of its technology and solutions. The role of Innosuisse – the Swiss Innovation Agency – is to promote science-based innovation in the interests of industry and society in Switzerland.
2018 | Capital increase – loan conversion executed
Loan conversion of the seed round investment into equity.
2017 | Start of Innosuisse funded First-in-man study
Clinical trial on ZuriMED’s first product, the BTB-Converter™ was approved by Swissethics and sponsored by Innosuisse (formerly Commission for Technology and Innovation in Switzerland [CTI]).
2016 | Seed round investment received
Investment in terms of convertible loan. ZuriMED moves into the newly opened Balgrist Campus.
2015 | Incorporation of ZuriMED Technologies AG
Winner of Venture Kick Final, Switzerland’s largest start-up acceleration program. Presenting 2nd best business plan by >>venture>>, the leading competition for entrepreneurs in Switzerland, a joint initiative of ETH Zurich, McKinsey & Company, Knecht Holding, Innosuisse and EPFL.
Careers
We are constantly seeking innovative talents. If you believe you are the perfect fit for our team, please send a spontaneous application to: hr@zurimed.com
We are looking forward to meeting you!